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Abstract
Background: The pharmaceutical market in Bangladesh is highly concentrated (top ten control around 70 % of the
market). Due to high competition aggressive marketing strategies are adopted for greater market share, which
sometimes cross limit. There is lack of data on this aspect in Bangladesh. This exploratory study aimed to fill this
gap by investigating current promotional practices of the pharmaceutical companies including the role of their
medical representatives (MR).
Methods: This qualitative study was conducted as part of a larger study to explore the status of governance in
health sector in 2009. Data were collected from Dhaka, Chittagong and Bogra districts through in-depth interview
(healthcare providers and MRs), observation (physician-MR interaction), and round table discussion (chief executives
and top management of the pharmaceutical companies).
Results: Findings reveal a highly structured system geared to generate prescriptions and ensure market share
instituted by the pharmaceuticals. A comprehensive training curriculum for the MRs prepares the newly recruited
science graduates for generating enough prescriptions by catering to the identified needs and demands of the
physicians expressed or otherwise, and thus grab higher market-share for the companies they represent. Approaches
such as inducements, persuasion, emotional blackmail, serving family members, etc. are used. The type, quantity and
quality of inducements offered to the physicians depend upon his/her capacity to produce prescriptions. The popular
physicians are cultivated meticulously by the MRs to establish brand loyalty and fulfill individual and company targets.
The physicians, willingly or unwillingly, become part of the system with few exceptions. Neither the regulatory
authority nor the professional or consumer rights bodies has any role to control or ractify the process.
Conclusions: The aggressive marketing of the pharmaceutical companies compel their MRs, programmed to maximize
market share, to adopt unethical means if and when necessary. When medicines are prescribed and dispensed more
for financial interests than for needs of the patients, it reflects system’s failed ability to hold individuals and entities
accountable for adhering to basic professional ethics, code of conduct, and statutory laws.
Keywords: Medical representatives, Pharmaceutical marketing, Pharmaceutical promotional gifts, Code of
Pharmaceutical Marketing Practices, Bangladesh
* Correspondence: ahmed.sm@icddrb.org
4Centre for Equity and Health Systems, icddr,b and Centre of Excellence for
Universal Health Coverage, icddr,b and JPGSPH, icddr,b and JPGSPH, BRAC
University, 5th Floor(Level-6), icddrb Building, 68 ShahidTajuddin Ahmed
Sharani, Mohakhali, Dhaka 1212, Bangladesh
Full list of author information is available at the end of the article
© 2015 Mohiuddin et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Mohiuddin et al. BMC Medical Ethics  (2015) 16:80 
DOI 10.1186/s12910-015-0075-z
Background
Promotion of pharmaceutical products involves “all in-
formational and persuasive activities by manufacturers
and distributors, the effect of which is to induce the pre-
scription, supply, purchase and/or use of medicinal
drugs” [1]. Pharmaceutical industries worldwide are
heavily involved in aggressive promotion of medical
products [2, 3]. Interactions between physicians and
pharmaceutical industries begin as early as medical
school days and continue well into professional life [4].
This interaction has increased significantly over the last
few decades. The pharmaceutical industries spend be-
tween 15 and 25 % of their total budget on promotional
activities, which is even higher in the third world coun-
tries [5]. The aggressive pharmaceutical promotion can
pose an ethical threat to professionalism because such
activities may influence prescribing behavior of physi-
cians without benefiting the patients [6]. This type of in-
teractions between pharmaceutical industries and
physicians were found to have negative outcomes that
compromise patient’s best interests [7, 8].
One of the tools commonly used by the pharmaceut-
ical companies is offering gifts (from stationeries to
household items to overseas trips to attend conferences,
etc.) to motivate physicians to write prescriptions [9–
12]. Acceptance of these gifts, especially the expensive
ones, obliges them to return favour by changing estab-
lished prescription norms and increasing sales [13]. Evi-
dence shows that, though the pharmaceutical companies
initiate the unethical marketing practice, physicians are
responsible for its continuation [14]. Conflicts of inter-
ests among the stakeholders prevent proper implemen-
tation of different regulations and guidelines formulated
by the government for ensuring ethical practices [15].
This problem is severe especially in low and middle-
income countries, where supervision and regulation of
the pharmaceutical industries are weak.
Bangladesh became the first low-income country to
develop an indigenous pharmaceutical industry [16, 17].
Now it claims a market share of more than 75 % of total
drug sales compared to 25 % before the National Drug
Policy was enacted in 1982. The pharmaceutical market
in Bangladesh is highly concentrated and limited to a
few big companies. The top ten companies have 68 % of
the market share and the top 20 have 78 %. Currently,
there are 265 allopathic drug manufacturing companies
in Bangladesh, of which 30 are considered large-scale
units that dominate the market [18]. Due to high com-
petition in the industry, aggressive marketing strategies
have been adopted by the different companies. In this
respect, promotion has become a useful tool to fight
competition. Like other countries, health professionals
in Bangladesh are also targeted by companies mainly
through medical representatives (MR) for promotion of
medicinal products. One to one visits from the MRs
have been proven to be the most effective way to pro-
mote drugs to physicians, because they can identify the
main motivators and decision-making styles of the per-
son they are selling to and adapt to their approach ac-
cordingly [19]. Visits from MRs are usually associated
with providing gifts, free samples, and advertising
campaigns.
There is a lack of data on MRs’ unethical practices for
promotion of pharmaceutical products in Bangladesh, al-
beit the presence of a Code of Pharmaceutical Marketing
Practices promulgated in 1994. This exploratory study
aimed to fill this data gap by investigating current prac-
tices of the pharmaceutical companies in this regard in-
cluding the role of pharmaceutical sales representativesin
influencing prescribing practices of the physicians. Find-
ings from this study are expected to help develop a drug
promotion practice which is transparent and accountable
and regulated by relevant authority.
Methods
This study was conducted as part of Bangladesh Health
Watch exercise to explore the status of governance in
health sector in 2009 [20]. The information sought being
of sensitive nature, we adopted a qualitative approach
and a purposive sampling strategy. Respondents were re-
cruited from Chittagong and Bogra districts besides the
capital Dhaka to explore variations in promotional prac-
tices and regulations, if any. The sites outside Dhaka
were selected based on consultation with the Technical
Advisor of the study team – Bogra being an important
drug distribution depo tin the northern part of the coun-
try and Chittagong being a representative of the south/
south-eastern part. Data were collected through in-
depth interviews with the healthcare providers and MRs,
real-time observation of a sample of the physician-MR
interactions, and round table discussions with chief ex-
ecutives and members of senior management of the
pharmaceutical companies (Table 1). Due to time and
resource constraints purposive sampling was done to se-
lect the respondents.
In-depth interviews
The in-depth interviews were sought to elicit informa-
tion on topics like role of MRs in detailing products to
healthcare providers, securing information on personal
preferences and life-styles of the providers, maintenance
of database, quantity and quality of gifts offered, person-
alized services provided, and adopting different other
promotional approaches to fulfill sales targets. Eleven in-
terviews were conducted with MRs of various pharma-
ceutical companies, both local and multinational; also
interviewed were 14 doctors, eight pallichikitshoks (vil-
lage doctors), and five representatives from DGDA
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(Directorate General of Drug Administration), BMDC
(Bangladesh Medical & Dental Council), BIRDEM
(Bangladesh Institute of Research & Rehabilitation in
Diabetes, Endocrine and Metabolic Disorders), Ibrahim
Medical College, and CAB (Consumer Association of
Bangladesh) (Table 1). A guideline was prepared after re-
view of the literature and discussion with technical ad-
viser of the study. Each interview lasted for a maximum
of 1 h.
Observation
To cross check the data obtained from the in-depth in-
terviews, realtime observations of the provider-MR in-
teractions were made in 16 sites from the three districts,
of which six were healthcare institutions (two private
and four public) and ten were drug retail outlets. In
these observations issues such as technical content of
the interaction, persuasion and compliance, nature and
amount of gifts offered including free drug samples, dis-
cussion over personal issues, etc. were noted. A struc-
tured form was used for this purpose. Observations were
done for the full length of interactions which lasted for
10 to 20 min on average.
Round-table discussion
Finally, a round-table discussion was held to know indus-
try perspectives on existing regulations for promotion of
pharmaceutical products and their role in promoting
more transparent and uniform practices. Chief and se-
nior executives (mostly from marketing departments)
of 11 local and multinational pharmaceutical compan-
ies attended this discussion (Table 1).
Analysis
Content analysis was done of the data from in-depth
interview with consolidation of sub-themes and themes.
Triangulation of data was done by eliciting information
on a particular issuefrom different sources e.g., data on
gifts offered (Fig. 1).
Ethical approval
The study proposal passed through the ethical review
board of the James P. Grant School of Public Health at
BRAC University. No invasive procedure was done. In-
formed verbal consent was obtained from the respon-
dents before conducting interview or documenting
physician-MR interaction. Anonymity of the respondents
was maintained at all stages.
Availability of data and materials
The comprehensive transcribed qualitative data are
available with the authors and archived in the repository
of the JPG School of Public Health at BRAC University.
Table 1 Respondents in the study
Data collection Sample
1. Observation (interactions between physicians and
MRs)
16 observations
a. Public & private institutes 4 Public Healthcare Institutions (medical college hospitals)
2 private healthcare facilities(doctor’s chamber/private clinic)
b. Pharmacies/drug shops 10 Drug shops from each site
2. In-depth Interview
a. Authorities 5 Authorities(DGDA, BMDC, BIRDEM, Ibrahim Medical College, CAB)
b. Doctors 14 Doctors
• 3 upazila health complexes (1 from each site)
• 3 district hospitals (1 from each site)
• 3 divisional medical college hospitals (1 from each site)
• 5 private healthcare facilities(doctors chamber/private clinic, 1 from each division
c. Pallichikitshoks (PCs, village doctors) 8 Pallichikitshoks (PCs, village doctors)
d. MRs 11 MRs (Interviews wereconducted with MRs of variouspharmaceutical companies, both
local and multinational)
3. Round-table discussion Participants from pharmaceutical companies:
13 participants (CEO, MD, ED, sales manager/senior marketing manager/Director Marketing,
manager medical affairs etc.) from 10 renowned pharmaceutical companies
Other Participants:
2 academicians (asst. professor of pharmacy and PhD student, pharmaceutical law and
marketing)
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Results
The qualitative findings obtained from in-depth inter-
view, healthcare provider-MR interaction and round-
table discussion are summarized below.
Medical Representatives (MR): the strategic link between
pharmaceutical companies and physicians
The large pharmaceutical market was principally driven
by the prescriptions of physicians. As such, the success
of the pharmaceutical companies depended on the ef-
fectiveness and efficiency of their MRs. They were
mainly science graduates, recruited through a competi-
tive process. After recruitment, they went through a
structured training programme which besides tech-
nical details on relevant products, also included how
to observe and assess doctors’ personalities and prefer-
ences. Thus, they gathered doctors’ personal informa-
tion such as family and lifestyle details, hobby,
personal interests, etc. which is termed as “history tak-
ing” by the MRs.
Categorization of doctors based on their ‘history’ and
how to approach them was also something that the MRs
were trained on. For example, one of the well-known
multinational companies categorized doctors (whom
they refer to as customers) according to who values what
(descriptions according to MR interview):
– Directing type: Doctors who have strong values and
maintain their dignity. They only prefer to have
information related to drug and not to talk about
anything else and have no interest in other benefits.
– Thinking type: Quiet in nature, they take time to
think before making any decision. They ask for
reference/evidence on the promotional briefs. They
usually prescribe the drugs only when they are
convinced.
– Affiliating type: These doctors welcome the MRs,
they like to listen to them and also express their
opinions. “It’s easier to work with this type of doctors,”
said an MR.
– Expressing type: These doctors often dominate the
conversation while talking to the MRs, they hardly
listen carefully to what the MRs say and usually do
not prescribe the products on offer. “They express
their demands quite frankly.”
This is only one example of how MRs were oriented
to face real life dealings with their customers. This
orientation of the MRs to meet their customers was used
to fulfill doctors’ demands and ultimately persuade them
into writing prescriptions as a favour in return (a ‘give
and take’ policy, according to one MR).
Dynamics of MR visits: blurring professional boundaries
The MR’s were encouraged to interact with physicians at
personal level which is also appreciated by the physicians.
Paying regular visits to physicians was one strategic way of
maintaining this relationship, and sometimes there was a
Fig. 1 Triangulation of data for arriving at core themes of the findings
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‘blurring of professional boundaries’ when it came to this
relationship. To illustrate:
“Sometimes, in one visit, the doctor becomes
convinced…sometimes, it take four to five visits…if the
gap is long between two visits, then the doctor forgets
about the drug, so we have to visit frequently to
highlight our products…” –One MR
A medicine specialist’s comment on the same issue
supported the MR’s claim:
“I automatically develop a soft corner for the MRs who
visit me regularly. Then I try to prescribe 2–3 of his
products. I think most of the doctors feel the same
way.”– A specialist doctor
Not all doctors were visited by the MRsin same fre-
quency. Doctors with high patient load were always pre-
ferred by the MRs. According to the MRs, they
categorized doctors based on their ‘potentiality’, deter-
mined by the number of patients visiting a doctor on
any given day which is a function of prescriptions that
can be generated. Besides patient load, ‘loyalty’ of the
doctors towards a company (i.e., inclination to prescribe
drugs of a particular company) was also an important
factor for determining the frequency of MR’s visit. Dur-
ing busy hours, MRs would drop in to exchange social
greetings with the doctors as an effective brand re-
minder which could result in a prescription soon after:
“In institutions, the doctors start prescribing drugs
from the morning but we are allowed to visit them
after 11 AM when the doctors are almost done with
their duty hours. So, even though I cannot visit him, I
go to him every day and give him a salaam so that he
remembers my brands” – An MR
Our observations revealed that the MRs of different com-
panies preferred to visit physicians early in the morning:
“… if we can visit doctors in the early morning, he will
have more opportunities to prescribe our brand which
is more beneficial for us”– An MR
Findings also reveal that MRs prefer public institutions
to private more since doctors in the former gave them
more time and allowed them to visit while the doctors
were attending patients. Patient load being higher in
these facilities, the probability of gaining prescription
share was also higher.
“Working in public sector health facilities is much
easier… we can enter there anytime and work, even
when the doctor is attending patients. But in private
hospitals and clinics, we have to strictly follow their
schedule…there are many restrictions! Usually rich
people come to these places and they also don’t want
to see us in the hospitals…”–An MR
The MRs spent the second half of their working days
in the chambers of private practitioners. All the MRs in
in-depth interviews said that they liked to interact with
the physicians during their private practice and nurture
the relationship. One MR said,
“In terms of visit, private chamber is more preferable
to us. Because, in institutions sometimes we have to
visit many doctors at a time and we have to ensure
that all the doctors get equal amount of samples or
gifts. But in private practice doctors sit in separate
room…so they are easy to deal with and we can
motivate them to prescribe our drugs.”– An MR
However, as in most of the times the relationship be-
tween an MR and a physician is one of ‘give and take’,
and it needs constant nurturing.
Achieving targets: monitoring prescriptions
‘Target’ is very important for the MRs; each pharma-
ceutical company had an individual target (monthly,
quarterly, annually) for its MRs. They received an in-
crement or incentive based on targets achieved,
which varied company to company. Thus, at the end
of each quarter, MRs are under pressure to meet
these targets by any means. Reportedly doctors, either
out of sympathy or out of exasperation, ended up in
prescribing some drugs under constant pressure from
the MRs, especially around the end of quarters. To
illustrate:
“MRs are always anxious about meeting their targets…
there are several MRs with whom I have good
relationship. One of those boys came to me the other
day and requested, ‘Sir, I need your help in fulfilling
my target. If I can make it this time, I’ll be able to go
to China.”– A physician
While doctors succumbing to the persuasion of the
MRs were common phenomena, there are exceptions
where unwavering determination of the doctor sent a
different message to the representatives:
“… there have been occasions when MRs have
appeared with blank cheques. I told them, ‘Do not
spoil the doctors like this. They are also humans
and they may also get temptated, so don’t do this
to us.” – A doctor
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To fulfill the all ‘pervasive’ targets, several strategies
were taken by the pharmaceutical companies. One of
these was monitoring of prescriptions of senior profes-
sors and very successful private practitioners. According
to the MRs, they were always tracking doctors and pro-
viding latest information to keep the companies’ data-
base up to date:
“When we visit a doctor we check whether the doctor
who agreed to prescribe our product actually did so,…
sometimes our company buys prescription survey data
from other companies. We usually check the
prescription from the patient…if our product is not
prescribed we keep reminding them through frequent
visits…”– An MR
This prescription monitoring by the MRs served other
purposes as well:
“…by monitoring prescriptions, we can identify
prescribing habits of a doctor. First, we can identify
which drugs a doctor usually likes, so that we can
promote those to increase our sale. Not only that, if a
doctor has any special relation with a company, we
can identify that by seeing most of the products of that
company in the prescription and can form our strategy
to [make them switch their preference].” -MR
The study also revealed that the top pharmaceutical
companies buy the prescription database from third par-
ties such as Intercontinental Marketing Services (IMS)
at a high cost. From this prescription database, they get
the region-specific list for brand preference of each doc-
tor which helps customize strategies appropriate to the
prescribing patterns.
Gifts, gifts, gifts: from a note pad and pen, to an overseas
trip for work or pleasure!
The most commonly used promotional materials offered
by the pharmaceuticals are literature on drugs, journals,
writing pads, pens and sample drugs. But there was an
increasing tendency of the pharmaceutical companies to
provide almost everything as gifts to the doctors:
“Pharmaceutical companies provide everything except
kaacha bazaar. Even during the last Eid they provided
perfumed rice (polao er chal), sugar, vermicelli (semai),
etc. So, it’s not easy to say what they don’t offer us.”–A
doctor
The gifts included items for both professional and
personal use. The professional items include sponsor-
ship for attending medical conference and seminar;
medical equipment and books; items for doctors’
waiting area (chairs, water filter, TV, etc.), personalized
visiting card, prescription pads & prescription folders;
and cash for products prescription. Items for personal
use include costs of air ticket and hotel accommodation
for pleasure trips with family and friends; decoration
for home; exclusive gifts such as home, flat, car, etc.
Other gifts include food items, mobile recharge cards,
Internet modem, cash or sponsorship for personal pro-
grammes such as wedding, birthday, naming ceremony
(Akika), etc.
The pharmaceutical companies used two approaches
for offering gifts. In proactive approach, some inex-
pensive gifts were given to the doctors each month
along with free samples of drugs during regular pro-
motional visits of the MRs. Brand names were usually
inscribed on these gifts so that it worked as re-
minders for the doctors. The other approach involved
offering inducements based on doctors’ demands, i.e.
“whatever s/he wants as gifts.” This culture of induce-
ment has even been extended to the family members
of doctors, especially the younger members. As illus-
trated by two MRs:
“Sometimes doctors want to take their family members
with them to the foreign trip and we sponsor them too.
Besides sponsoring seminar and workshops, we also give
doctors different kind of electronic and household items.
We give every possible item they ask for…”–An MR
“Some doctors demand computer, TV, fridge, AC,
mobile phone, laptop, etc. Mobile bill, electric bill,
attendant bill, driver’s salary, paper bill, etc. - for
everything they have contract with companies…” –An
MR
This is also supported by a doctor who recalled:
“Dhaka-Singapore air tickets, cars, houses, and even
family or household items – these are the things that
doctors get. … Doctor X has bought a plot in
Dhanmondi. Lots of people are becoming owners of
cars and houses in this way. You can even call it a
competition these days [of who receives more in terms
of gifts].”–A doctor
The changing pattern of promotional activitieshad an
impact on the prescription habits of the doctors which
was acknowledged by a doctor:
“Promotional activities influence our prescription
habit. I think that the doctors realize this but they
stilldo it. When a doctor accepts a gift from a
company, he knows why he is offered that….a certain
obligation develops towards that company…”
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But there are exceptions too. A professor of a private
medical college explained:
“…doctors are frustrated of this corrupt system and the
way it compels them to become a part of it.”
The study reveals that doctors generally are not inter-
ested in receiving product literature from MRs, rather
they are more interested in drug samples that MRs bring
as promotional items. It is a common complaint that a
substantial proportion of the drug samples for the physi-
cians ultimately land in the retail drug outlets. Here are
two quotes from MRs:
“…we usually place the samples on the table (of the
doctor)…it’s not right to sell these. But, we cannot
question the doctors about this, neither the company
takes any action in this regard”. –An MR
“Pharmaceutical promotion has now reached the stage
of bribing. In earlier days doctors were given drug
samples for their poor patients. ‘Not for sale’ was
printed on the packets of the drugs and the doctors
gave it to their patients. But nowadays, doctors are
selling the drugs…they have taken their profession as a
business”.– An MR
Market segmentation
The MRs of large and medium scale companies primar-
ily target doctors to promote their products while the
MRs of smaller companies usually target village doctors
and the likes to sell their products. MRs agreed unani-
mously that they spent more time in detailing to village
doctors rather than MBBS doctors, because village doc-
tors were less knowledgeable about drugs and received
MR visits more enthusiastically. Village doctors also
expressed an interest in maintaining friendly relationship
with the MRs and often bought drugs only from MRs
who were “friends” with them.
Awareness about Code of Pharmaceutical Marketing
Practices (CPMP)
The MRs were unaware about the existing code on drug
promotion and marketing practices. Many doctors also
mentioned that they were unaware about the code:
“I don’t have much idea about the CPMP. It is not
clear to me which practices are considered unethical
in our country. This needs to be clearly communicated
to the doctors and also to the pharmaceutical
companies. The Department of Drug Administration
should then take an active role in preventing these
unethical practices. I don’t think they are playing any
role in this regard at present.” – A doctor
The MRs perceived an ‘ethical doctor’ as one who is
loyal to one particular company and an ‘unethical doc-
tor’ is one who maintained contracts with multiple
companies.
Perspectives of the senior executives of the
pharmaceutical companies
According to the executives of the pharmaceutical com-
panies, the Code is voluntary. For their own interest,
they try to abide by it. They said that they took prior ap-
proval from the authority (DGDA) for the literatures (in-
cluding other promotional materials) before presenting
them to doctors. The MRs are deployed only to detail
the literature to the doctors. They claimed that the doc-
tors are too busy to go through the literature on their
own and most of the literatures landed in the trash.
They argued that the companies don’t give unreasonable
targets to the MRs as this would lead them to resort to
unscrupulous means.
The top executives of the pharmaceutical companies
also contended that inadequate capacity of the DGDA
(both technical and human resource capacity) to moni-
tor and regulate the market was responsible for uneth-
ical promotional practices. However, as the market is
very competitive, they emphasized on the need for self-
regulation, which according to them, is followed for the
benefits of the industry. The executives also pointed out
that the unregistered/unregulated drug retail outlets
(drug shops) are the places where unethical promotional
practices are rampant and attention should be directed
there to put a check to these practices. They also reiter-
ated the necessity for an official schedule of Over-the-
Counter drugs to check unethical practices by the infor-
mal healthcare providers.
Discussion
This study was done as part of a larger study by
Bangladesh Health Watch 2009 which explored issues
related to governance in the health sector including the
pharmaceutical sector [20]. It aimed to investigate the
extent of ethical procedures followed in the marketing
practices of the pharmaceutical companies and the role
of their MRs in this process. Findings reveal a structured
and evidence-based drug promotion strategy instituted
by the pharmaceutical companies which frequently vio-
lates ethics. The MRs are trained to act as a tool to
achieve targeted market share through building personal
relationship with the physicians and catering to their
needs and demands, expressed or otherwise, and fulfill
their personal targets as part of gaining higher market-
share for the companies they represent. The physicians,
willingly or unwillingly, become a pawn of the system
with few exceptions. These are discussed with context in
the following paragraphs.
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A highly structured system to generate prescriptions and
ensure market share
As in other south Asian countries [2, 8], the pharma-
ceutical companies in Bangladesh have developed a
comprehensive, evidence-based system (through ‘history’
taking of physicians and monitoring of prescriptions) in
order to guarantee that enough prescriptions are gener-
ated to ensure targeted market share. This system is
based on the army of the ‘MRs’ since they are found to
be the best tool of promotion for a pharmaceutical com-
pany [21–23]. An evidence-based training curriculum
prepares the newly recruited science graduates to learn
how to study and assess the likes and dislikes, inclina-
tions, and financial needs and demands of their ‘cus-
tomers’, i.e. the physicians, besides technical knowledge
on relevant products. They keep track of these and are
ready to serve them when needed.
A variety of approaches are used such as giving gifts
(from minor professional items to costly personal use
items), persuasion, emotional blackmailing, support to
the family members, and support in times of personal
emergencies, etc. In doing these, they pay little heed to
the laws or ethics. The MRs try to develop an intimate
relationship with the physicians which they exploit to
achieve their ‘targets’ [24]. The success of the MR’s car-
eer also depends on fulfilling the targets on time, which
may result in stress with health consequences [25]. Thus,
MRs appear to be pawns in a system, pre-programmed
to achieve a certain target, whatever the efforts and
costs. In the ‘unholy’ alliance of the pharmaceutical com-
panies, MRs and the physicians, they are the least
powerful [26].
Offering gifts: crossing the ethical boundaries
The amount, quantity and quality of gifts offered to the
physician depend upon his capacity of generating pre-
scriptions. Those with high popularity are cultivated me-
ticulously by the MRs to establish brand loyalty and
generate enough prescriptions to fulfill both individual
and company targets. However, the fresh graduates are
nurtured from the very beginning to ‘co-opt’ them into
the system. It is interesting that personal use items, in-
cluding cash, accounts for a large portion of the gifts on
offer which transcend all ethical boundaries. Free ‘sam-
ple’ drugs are also a problem [27, 28] especially when
these land in retail outlets. The willing and sometimes
‘helpless’ surrender of the physicians to the aggressive
marketing techniques of the pharmaceuticals (through
the MRs) is mainly responsible for sustaining and nour-
ishing the system [29]. This is compounded by the ab-
sence of any oversight from either the professional
bodies or the regulatory bodies to discourage or curb
this. Interestingly, the most preferred information source
perceived by doctors such as educational programmes
like conferences and seminars [30] is given hardly any
importance in Bangladesh.
The regulatory environment
The MRs are not aware about the existing code of mar-
keting practices for pharmaceuticals, neither the major-
ity of the doctors. There are also no efforts on the part
of the regulators (DGDA) to disseminate this informa-
tion. One reason frequently cited by DGDA is the short-
age of their manpower to match the activities of the
increasing number of pharmaceutical companies. Also,
complete absence of the physicians’ professional bodies
like Bangladesh Medical & Dental Association in oversee-
ing the professional conducts of its members has given a
free reign to the pharmaceuticals in doing whatever they
deem necessary to boost sales of their products.
Conclusions
Pharmaceutical companies expand market and maintain
high profit through aggressive promotion of their prod-
ucts in Bangladesh without any hindrance. These pro-
motional activities compel the MRs, programmed to
maximize sale of products, to adopt unethical means if
and when necessary. When medicines are prescribed
and dispensed more for financial interests of the pre-
scribers and dispensers than for needs of the patients, it
reflects failure of the system’s ability to hold individuals
and entities accountable for adhering to basic medical
ethics, standard procedures, norms, laws and regula-
tions. Both the regulatory and professional bodies have a
role to play. Without increasing transparency and ac-
countability in drug promotion the issues of public
health and consumer rights will remain tangential.
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